1 min read

ID: 684242

Short Link: https://gregory-ms.com/articles/684242/

Discovery Date: 14 July 2022, 11:07:04 UTC

Published Date: 2022-07-13 10:00:00

Source: PubMed

Link: https://pubmed.ncbi.nlm.nih.gov/35822550/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220714070703&v=2.17.7

Manual Selection: true

Machine Learning Gaussian Naive Bayes Model: false

Abstract

Preventing neurodegeneration-associated disability progression in patients with multiple sclerosis (MS) remains an unmet therapeutic need. As remyelination prevents axonal degeneration, promoting this process in patients might enhance neuroprotection. In demyelinating mouse lesions, local overexpression of semaphorin 3F (Sema3F), an oligodendrocyte progenitor cell (OPC) attractant, increases remyelination. However, molecular targeting to MS lesions is a challenge. A clinically relevant paradigm…

Noun Phrases in Title

  • Genetically modified macrophages
  • myelin repair
This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by donating what you can to pay for the server costs.